Return to search results.
Complete title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
|Research Study Number||20121103|
|Principal Investigator||Veena Shankaran|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Gastrointestinal Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.